

AMARIN CORP PLC\UK  
Form 8-K  
April 18, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

**Date of Report (Date of Earliest Event Reported): April 18, 2011**

**Amarin Corporation plc**

(Exact name of registrant as specified in its charter)

England and Wales  
(State or other jurisdiction  
of incorporation)

0-21392  
(Commission  
File Number)

Not applicable  
(I.R.S. Employer  
Identification No.)

Edgar Filing: AMARIN CORP PLC\UK - Form 8-K

**First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge,**

**Dublin 4, Ireland**  
**(Address of principal executive offices)**

**Not applicable**  
**(Zip Code)**

**Registrant's telephone number, including area code: +353 1 6699 020**

**Not Applicable**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On April 18, 2011, Amarin Corporation plc (the Company ) issued a press release announcing the top line results of its ANCHOR study, a Phase 3 clinical trial of its lead drug candidate AMR101. The full text this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated April 18, 2011

\* \* \*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 18, 2011

Amarin Corporation plc

By: /s/ John Thero  
John Thero  
President

**Exhibit Index**

Exhibit No.	Description
99.1	Press Release, dated April 18, 2011